

This Listing of Claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

Claim 1 (currently amended): A method of screening for ~~diagnosing~~ prostate cancer, the method comprising the step of assaying a level ~~detecting increased levels~~ of a human endogenous MMTV-like subgroup 2 (HML-2) retrovirus encoded expression product in a patient prostate or blood sample ~~relative to a negative control sample~~, wherein an increased level ~~levels~~ of at least 150% relative to a control sample level indicates that the patient should undergo further testing for the presence ~~are indicative of a diagnosis of prostate cancer, and wherein said expression product is an RNA corresponding to the gag or pol domain of said retrovirus, or is a polypeptide encoded by said RNA.~~

Claim 2 (canceled)

Claim 3 (previously presented): The method of claim 1 wherein the patient sample is a prostate sample.

Claim 4 (previously presented): The method of claim 1 wherein the expression product is an RNA comprising SEQ ID NO:155.

Claim 5 (previously presented): The method of claim 4 wherein the expression product is an RNA comprising SEQ ID NO:5.

Claim 6 (previously presented): The method of claim 4 wherein SEQ ID NO:155 is at the 5' end of the RNA.

Claim 7 (currently amended): The method of claim 1 ~~2~~ wherein the RNA comprises SEQ ID NO:155 and SEQ ID NO:5.

Claims 8-9 (canceled)

Claim 10 (currently amended): The method of claim 1 ~~9~~ wherein the polypeptide is detected using an antibody.

Claims 11-12 (canceled)

Claim 13 (currently amended): The method of claim 1 ~~2~~ further comprising the step of enriching RNA in the patient sample.

Claim 14 (previously presented): The method of claim 1 wherein the expression product is detected using PCR, SDA, SSSR, LCR, TMA or NASBA.

Claim 15 (previously presented): The method of claim 14 wherein the PCR is RT-PCR.

Claims 16-38 (canceled)